The Food and Drug Administration on Friday approved a nasal spray intended to treat adults who frequently wake up at night to urinate.
The behavior, called nocturia, is a common symptom of numerous conditions like congestive heart failure or bladder disease. The nasal spray, Noctiva, represents the first FDA-approved treatment for this condition, according to the agency.
Thirty minutes before going to bed, adults administer the nasal spray, which increases the kidney's ability to absorb water and causes less urine production.
Serenity Pharmaceuticals developed the drug, which contains a boxed warning for causing low sodium levels in the blood.
More articles on supply chain:
Lawmakers seek to accelerate approvals with Reauthorized Generic Drug User Fee Act
Physician avoids high cost of EpiPens with homemade device
4 reasons supply chain managers could one day become CEOs